Mental Health and PreP (SAM-P)

Prevalence of Major Depressive Disorder in the Population of People Followed up for HIV PREP Consulting the Infectious Diseases Department of Saint-Antoine Hospital, APHP and in General Practices

According to ANSM, by June 2023, almost 85,000 people living in France had initiated medical monitoring for HIV PrEP since 2016. Since 2021, HIV PrEP can be prescribed for the first time in community clinics, in addition to hospital structures such as CeGIDDs, or by doctors specialising in infectious diseases, making this preventive treatment for HIV more accessible. The population undergoing PrEP treatment is typically men who have sex with men (MSM), living in the Ile-De-France region, with an average age of 36 and social security cover.

In view of the growing number of people being monitored for HIV PrEP, particularly in general practice, which accounts for 80% of prescribers in private practice, and which will increase from 19% of initiations in 2021 to 42% in 2023, it seems essential not to ignore the occurrence of comorbidities, in order to better prevent or detect pathologies that may occur during the monitoring of these people. It appears that mental illnesses, and in particular major depressive disorder or anxiety disorders, as well as addictions, are present in many people receiving PrEP treatment. A study carried out in Canada found a prevalence of depressive disorders of almost 24%, alcohol use disorders for almost 32% and moderate to severe substance use for 43.3% of their study population. While some studies have highlighted the possibility of a reduction in anxiety, depression and addictions in patients using HIV PrEP, no study seems to have looked at the prevalence of depression in this specific population, which is exposed to more traumatic events, aggression or violence, and addictive behaviour, themselves associated with more depressive or anxious symptoms.

To date, there is little information on the psychiatric comorbidities of patients undergoing HIV PrEP, apart from elements purely associated with PrEP (compliance, adherence to treatment or follow-up). In the context of prevention as part of primary care monitoring, it seems necessary to better identify these comorbid pathologies in this specific population, using the opportunity of PrEP monitoring to initiate treatment where appropriate.

Study Overview

• Status: Not yet recruiting
• Conditions: Major Depressive Disorder in Patients Taking PrEP
• Intervention / Treatment: Other: Major depressive disorder scale

Detailed Description

Given the gradual opening up of general practitioners to the initial prescription and monitoring of PrEP, their role in the identification and prevention of mental illness remains more than useful, and they can compensate for certain shortcomings in the context of hospital monitoring, boasting a certain territorial proximity, greater availability and more comprehensive patient management. Given the lack of data in France on the prevalence of mental illness, and in particular of major depressive disorder, the investigator wanted to gain a better understanding of these psychiatric illnesses in our patients undergoing PrEP in general practices and hospitals, by carrying out questionnaires recommended by the Haute Autorité de Santé (HAS) for monitoring the general population. Our study will thus make it possible to improve the data concerning the prevalence of major depressive disorder in patients being monitored for PrEP, potentially playing a role in adherence to treatment. Secondly, this study aims to provide a better description of the risk factors for these mental pathologies in this specific population by describing socio-demographic characteristics and sexual behavior, and to determine whether or not PrEP takes precedence over psychiatric management and the prevalence of psychotropic drugs in patients undergoing PrEP treatment.

The investigator want to assess the prevalence of anxiety and depressive disorders using hetero-questionnaires recommended by the French National Authority for Health, namely the Hamilton Depression Rating Scale (HDRS) for depression. Our secondary aim is to investigate the potential clinical characteristics of these disorders in patients undergoing PrEP treatment, for future, more substantial studies. Thus, by carrying out these questionnaires, screening for these disorders could be accompanied by a change in their medical management, through standardized management of depression, as described by the HAS.

• Study Type: Interventional
• Enrollment (Estimated): 600
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Thibault Chiarabini, MD; Phone Number: 01 71 97 01 19; Email: thibault.chiarabini@aphp.fr
• Study Contact Backup: Name: Karine Lacombe, MD-PhD; Phone Number: 01 71 97 01 19; Email: Karine.lacombe@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Any adult being treated for HIV PrEP at one of the centres taking part in the study
• Have French social security coverage

Exclusion Criteria:

• Follow-up to HIV
• First consultation for PrEP
• Limited understanding of French to answer questionnaires

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: One group to study a prevalence	Other: Major depressive disorder scale; Pass HDRS to patient taking PrEP to study prevalence of Major Depressive Disorder; Other Names: Hamilton Depression Rating Scale (HDRS)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major Depressive Disorder	Pass questionnary to evaluate the prevalence of major depressive disorder	at inclusion visit Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Describe the factors associated with this psychiatric entity in the overall study population	Pass questionary	at inclusion visit Day 1
Clinical characterization of depressive episodes	Evaluate the contribution of questionary in the screening of depressive episodes with regard to the clinician's response	at inclusion visit Day 1
Description of the the treatment plan for depressive disorders, i.e. before or after PrEP monitoring	Pass questionary	at inclusion visit Day 1
Prevalence of co-prescriptions	Describe the prevalence of co-prescriptions of HIV PrEP and psychotropic drugs (drugs used to treat mental illness).	at inclusion visit Day 1

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Thibault Chiarabini, MD, Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2025
• Primary Completion (Estimated): September 1, 2025
• Study Completion (Estimated): September 1, 2025

Study Registration Dates

• First Submitted: April 9, 2025
• First Submitted That Met QC Criteria: April 17, 2025
• First Posted (Actual): April 25, 2025

Study Record Updates

• Last Update Posted (Actual): April 25, 2025
• Last Update Submitted That Met QC Criteria: April 17, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: Depression; HIV; mental disorders; Pre-exposure Prophylaxis
• Additional Relevant MeSH Terms: Mental Disorders; Behavioral Symptoms; Mood Disorders; Depression; Depressive Disorder; Depressive Disorder, Major
• Other Study ID Numbers: APHP241798

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No